Timing of antiretroviral drugs during tuberculosis therapy [3]

New England Journal of Medicine

Volumn 362, Issue 22, 2010, Pages 2138-

  Kadhiravan, Tamilarasu ^a  

^a JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

TUBERCULOSTATIC AGENT;

EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MULTIDRUG RESISTANT TUBERCULOSIS; PRIORITY JOURNAL; TUBERCULOSIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-RETROVIRAL AGENTS; ANTITUBERCULAR AGENTS; CD4 LYMPHOCYTE COUNT; CONFOUNDING FACTORS (EPIDEMIOLOGY); DRUG ADMINISTRATION SCHEDULE; HIV INFECTIONS; HUMANS; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 77953158081     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (3)

1. Pepper DJ, Rebe K, Morroni C, Wilkinson RJ, Meintjes G. Clinical deterioration during antitubercular treatment at a district hospital in South Africa: the importance of drug resistance and AIDS defining illnesses. PLoS One 2009;4(2):e4520.
2. Hassim S, Shaw PA, Sangweni P, et al. Detection of a substantial rate of multidrug-resistant tuberculosis in an HIV-infected population in South Africa by active monitoring of sputum samples. Clin Infect Dis 2010;50:1053-1059
3. Cowley D, Govender D, February B, et al. Recent and rapid emergence of W-Beijing strains of Mycobacterium tuberculosis in Cape Town, South Africa. Clin Infect Dis 2008;47:1252-1259